Contemporary Management of Behçet’s Disease: Merging Multidisciplinary Approaches With Emerging Therapies
  • CME

In this concise activity, Yusuf Yazici, MD, overviews key considerations for the diagnosis and treatment of Behçet’s disease, including patient demographics, genetic associations, and historical and emerging treatment options.
Yusuf Yazici, MD
Physicians: maximum of 0.6 AMA PRA Category 1 Credits
Released: November 18, 2019 Expiration: November 17, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply knowledge of the epidemiology, pathophysiology, and risk factors for Behçet’s disease to inform a timely and appropriate diagnosis
  • Evaluate the safety and efficacy of the current and emerging treatment options for Behçet’s disease, applying an evidence-based approach to treatment selection and patient care


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Yusuf Yazici, MD

Clinical Associate Professor of Medicine
Department of Rheumatology
New York University School of Medicine
New York, New York

Yusuf Yazici, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Celgene, and Genentech and consulting fees from Celgene and Sanofi.


Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Bill O'Dell

Director, CME Program Development

Bill O’Dell has no relevant conflicts of interest to report.
Jennifer Votta

General Manager

Jennifer Votta has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
David C. Howard

Editorial Contributor

David C. Howard has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists as the primary audience and other specialists who may encounter and be involved in coordinated care for patients with Behçet’s disease.


The goal of this activity is to improve participants’ competence in recognizing signs and symptoms of Behçet’s disease, and to incorporate current and emerging treatment strategies to improve patients’ quality of life and health outcomes.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.6 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 18, 2019, through November 17, 2020:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO faculty Dr Kenneth Calamia discusses the clinical features of Behçet’s disease and how to weigh symptoms when making a diagnosis

Kenneth T. Calamia, MD Released: January 28, 2020

CCO faculty Dr. Yusuf Yazici on treating mucocutaneous manifestations such as oral ulcers in Behçet’s: apremilast, colchicine, dapsone, pentoxifylline, thalidomide

Yusuf Yazici, MD Released: December 16, 2019

Slides from Yusuf Yazici, MD, and Clinical Care Options with key considerations for diagnosis and treatment of Behcet’s disease

Yusuf Yazici, MD Released: November 18, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?